- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05245292
3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)
An Open Label, Single Arm Study of the Safety and Antiretroviral Activity of Two Long-acting Broadly Neutralizing Antibodies Plus an IL-15 Superagonist in ART-treated Adults Living With HIV During Analytical Treatment Interruption
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The proposed study is a phase 1, open label study of the safety and antiretroviral activity of the 3BNC117-LS plus 10-1074-LS broadly neutralizing antibody (bNAb) combination plus N-803, an IL-15 superagonist complex, in ART-treated individuals living with HIV during interruption of ART.
Thirty-six eligible participants will be enrolled sequentially and will be assigned to Group A or Group B after Monogram PhenoSense Assay results become available: Group A (n=18) - participants with 3BNC117 and 10-1074 IC90 less or equal to 1 mcg/mL and MPI greater or equal to 98% by the Monogram PhenoSense assay using PBMCs; Group B (n=18) - all other participants, including participants from whom the PhenoSense Assay (PBMC) does not yield a result.
Participants will discontinue ART on day 2 (2 days after the first antibody infusions) and will be followed for up to 72 weeks while off ART and for 24 weeks after ART is resumed.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Recruitment Specialist
- Phone Number: 800-782-2737
- Email: rucares@rockefeller.edu
Study Contact Backup
- Name: Marina Caskey, MD
- Email: mcaskey@rockefeller.edu
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Recruiting
- The Rockefeller University
-
Contact:
- Recruitment Specialist
- Phone Number: 800-782-2737
- Email: rucares@rockefeller.edu
-
Contact:
- Katrina Millard, ANP
- Phone Number: 212-327-7546
- Email: kmillard@rockefeller.edu
-
New York, New York, United States, 10021
- Recruiting
- Weill Cornell Medicine, Cornell Clinical Trials Unit
-
Contact:
- Timothy Wilkin, MD
- Phone Number: 212-746-4177
- Email: tiw2001@med.cornell.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- Perelman School of Medicine University of Pennsylvania
-
Contact:
- Kendra Poirier
- Phone Number: 267-328-7016
- Email: poirierk@sas.upenn.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male and females, age 18 to 70.
- Confirmed HIV-1 infection.
On antiretroviral therapy with plasma HIV-1 RNA levels of < 50 copies/ml and no reported interruption of ART for 7 consecutive days or longer for at least 48 weeks, and < 20 copies/ml at screening.
NOTE: At least two Viral Load (VL) measurements within 48 weeks prior to the Step 0 screening visit must be available for review. A single plasma HIV-1 RNA > 50 copies/mL but < 200 copies/mL that is followed by an HIV-1 RNA <50 copies/mL is permitted.
- Current CD4+ T cell counts > 450 cells/mcL, CD4+ T cell % ≥ 15%, and CD4+ T cell count nadir of ≥ 200 cells/mcL.
- If on an NNRTI-based regimen, willing to switch to an integrase inhibitor-based regimen for at least 4 weeks prior to discontinuing ART.
- For participants who can become pregnant (i.e., participants who have not been post-menopausal for at least 24 consecutive months, who have had menses within the preceding 24 months, or who have not undergone surgical sterilization, specifically hysterectomy and/or bilateral oophorectomy), negative pregnancy test at screening (Step 0) and within 48 hours prior to day 0 (Step 1 entry).
- Participants who can become pregnant must agree to use two methods of contraception, one of which must be from the highly effective methods for contraception listed below. Barrier methods of contraception are permitted for the second method of contraception. Contraception must be used from 10 days prior to the first of the investigational products (IP), while receiving the IPs, for 12 months after the last IP dose and until ART is reinitiated and viral suppression is achieved.
- Participants who can impregnate a partner and who are engaging in sexual activity that could lead to pregnancy must agree to use condoms from 10 days prior to the first dose of the investigational products (IP), while receiving the IPs, and for 12 months after the last IP dose to avoid impregnating a partner who can get pregnant.
- Willingness to use barrier protection (male or female) during sexual activity during analytical treatment interruption (ATI) and until viral re-suppression for those who re-start ART.
Exclusion Criteria:
- History of AIDS-defining illness within 3 years prior to enrollment.
- History of systemic corticosteroids (e.g. an equivalent dose of prednisone of > 20 mg daily for > 14 days), immunosuppressive anti-cancer, interleukins, systemic interferons, systemic chemotherapy or other medications considered significant by the trial physician within the last 6 months.
- Any clinically significant acute or chronic medical condition (e.g. such as autoimmune diseases, cirrhosis), other than HIV infection, that in the opinion of the investigator would preclude participation.
- History of or current clinical atherosclerotic cardiovascular disease (ASCVD), as defined by 2013 ACC/AHA guidelines.
- QTcF interval ≥ 440 ms at screening.
- Any history of an HIV-associated malignancy, including Kaposi's sarcoma, or any type of lymphoma or virus-associated cancers.
- History of Progressive Multifocal Leukoencephalopathy (PML).
- Active or recent non-HIV-associated malignancy requiring systemic chemotherapy or surgery in the preceding 36 months or for whom such therapies are expected in the subsequent 12 months;
- Hepatitis B or C infection as indicated by the presence of Hepatitis B surface antigen (HBsAg) or hepatitis C virus RNA (HCV-RNA) in blood.
- Participants with known hypersensitivity to any constituent of the investigational products.
- Pregnancy or lactation.
- ART initiated during acute infection (defined as p24, HIV NAAT, or HIV RNA PCR positive, and negative or indeterminate HIV antibody testing).
- Receipt of cabotegravir-LA IM or rilpivirine-LA IM within 24 months prior to Step 1 study entry.
- Known resistance to all drugs within two or more ARV drug classes.
Laboratory abnormalities in the parameters listed below:
- Absolute neutrophil count < 1,000 cells/microlitre;
- Hemoglobin < 10 gm/dL;
- Platelet count < 100,000 cells/microlitre;
- ALT > 1.5 x ULN;
- AST > 1.5 x ULN;
- Total bilirubin > 1.5 x ULN;
- eGFR < 60 mL/min/1.73m2;
- Any history of receipt of therapeutic HIV vaccine or HIV monoclonal antibody therapy.
- Participation in any clinical study of an investigational product within 12 weeks prior to study entry (day 0) or expected participation in such a study during this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 3BNC117-LS + 10-1074-LS + N-803
3BNC117-LS dosed at 30 mg/kg IV, day 0 10-1074-LS dosed at 10 mg/kg IV, day 0 N-803 dosed at 6 mcg/kg, SC, 8 doses every 3 weeks (week 1 through week 22)
|
Intravenous infusion of 3BNC117-LS at 30 mg/kg
Other Names:
Intravenous infusion of 10-1074-LS at 10 mg/kg
Other Names:
Subcutaneous injections of N803 at 6 mcg/kg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment-related Grade 3 adverse events and serious adverse events
Time Frame: 72 weeks
|
The number of participants with treatment-related solicited and unsolicited grade 3 and serious adverse events (including confirmed laboratory abnormalities), or premature study treatment discontinuation due to an adverse event (regardless of grade).
|
72 weeks
|
Any serious adverse events
Time Frame: 72 weeks
|
The number of participants with serious adverse events, regardless of relationship to 3BNC117-LS, 10-1074-LS and N-803.
|
72 weeks
|
Dosing completion
Time Frame: 24 weeks
|
The proportion of participants who complete dosing with 3BNC117-LS, 10-1074-LS and N-803.
|
24 weeks
|
Viral rebound before or at week 24 post withdrawing ART
Time Frame: 24 weeks
|
The number of participants experiencing viral rebound, defined as confirmed HIV-1 RNA >200 copies/mL at or prior to week 24 of ART discontinuation.
|
24 weeks
|
ART not restarted by weeks 60 and 72
Time Frame: 72 weeks
|
The proportion of participants who do not meet ART restart criteria by weeks 60 and 72.
|
72 weeks
|
ART not restarted when bNABs below threshold
Time Frame: 72 weeks
|
The proportion of participants who do not meet ART restart criteria for 12 or more weeks after bNAbs are below a threshold of 10 mcg/ml.
|
72 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment-related Grade 2 adverse events
Time Frame: 72 weeks
|
The number of participants with treatment-related solicited and unsolicited grade 2 adverse events.
|
72 weeks
|
Viral rebound through Step 2
Time Frame: 72 weeks
|
The number of participants experiencing viral rebound, defined as confirmed HIV-1 RNA >200 copies/mL, through Step 2 of the study.
|
72 weeks
|
Time from ART withdrawal to re-initiating ART
Time Frame: 72 weeks
|
Time from ART withdrawal to virologic or immunologic criteria (i.e.
viral load, CD4 cell count, or development of severe acute retroviral syndrome) to reinitiate ART.
|
72 weeks
|
Viral rebound determined by Monogram assay
Time Frame: 72 weeks
|
Time to viral rebound (confirmed HIV-1 RNA >200 copies/mL) across different 3BNC117-LS and 10-1074-LS IC90s cut points determined by the Monogram PhenoSense assay.
|
72 weeks
|
Size of latent HIV-1 reservoir
Time Frame: 72 weeks
|
Size of the latent HIV-1 reservoir, measured by IPDA and/or other appropriate assay, before, during (Step 1) and after dosing with 3BNC117-LS, 10-1074-LS and N-803 (Step 2), and after antibody concentrations have declined below a therapeutic threshold.
|
72 weeks
|
Changes in HIV-1 specific T Cell immune responses
Time Frame: 72 weeks
|
Changes in HIV-1 specific T cell immune responses in peripheral blood, measured by ELISPOT, before, during (Step 1) and after dosing with 3BNC117-LS, 10-1074-LS and N-803 (Step 2), and after antibody concentrations have declined below a therapeutic threshold.
|
72 weeks
|
Half-life of 3BNC117-LS and 10-1074-LS
Time Frame: 72 weeks
|
Half-life of 3BNC117-LS and 10-1074-LS, when administered in combination with N-803 to individuals with HIV during ART interruption.
|
72 weeks
|
Anti-drug antibodies (ADA)
Time Frame: 72 weeks
|
The proportion of individuals with treatment-induced ADA against each bNAb or N-803 and magnitude of the response.
|
72 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma rebound virus sensitivity
Time Frame: 48 weeks
|
The relationship between plasma rebound virus sensitivity to 3BNC117-LS and 10-1074-LS and serum levels of 3BNC117-LS and 10-1074-LS at the time of viral rebound.
|
48 weeks
|
HIV-1 specific T cell immune response changes
Time Frame: 72 weeks
|
Changes in HIV-1 specific T cell immune responses in peripheral blood, measured by assays such as polyfunctional intracellular cytokine staining (ICS) and viral inhibition assay before, during and after immunotherapy with 3BNC117-LS and 10-1074-LS in combination with N-803.
|
72 weeks
|
Latent HIV-1 reservoir composition
Time Frame: 72 weeks
|
Composition of the latent HIV-1 reservoir before and after immunotherapy with 3BNC117-LS and 10-1074-LS in combination with N-803 evaluated by Q4PCR or other appropriate assays that may become available.
|
72 weeks
|
Neutralization sensitivity
Time Frame: 72 weeks
|
Neutralization sensitivity by TZM/bl assay (IC50, IC80 and IC90) of representative viruses during ART and antibody suppression, and of plasma rebound viruses to 3BNC117 and 10-1074.
|
72 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Marina Caskey, MD, The Rockefeller University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Slow Virus Diseases
- Urogenital Diseases
- Genital Diseases
- HIV Infections
- Acquired Immunodeficiency Syndrome
- Physiological Effects of Drugs
- Antineoplastic Agents
- Immunologic Factors
- Antibodies
- Antibodies, Blocking
- Immunoglobulins
- Antibodies, Monoclonal
- Antineoplastic Agents, Immunological
Other Study ID Numbers
- MCA-1031 (ES38918)
- 1U01AI145921 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Human Immunodeficiency Virus
-
Merck Sharp & Dohme LLCWithdrawnHIV-1 | Immunodeficiency Virus Type 1, Human | Human Immunodeficiency Virus Type 1 | Human Immunodeficiency Virus 1
-
MacroGenicsNational Institute of Allergy and Infectious Diseases (NIAID); National Institutes... and other collaboratorsActive, not recruitingHuman Immunodeficiency Virus I Infection | Immunodeficiency Virus Type 1, Human | Human Immunodeficiency Virus Type 1United States
-
National Institute of Allergy and Infectious Diseases...CompletedHuman Immunodeficiency Virus (HIV) | Human Immunodeficiency Virus PreventionUnited States
-
EMD SeronoCompletedHuman Immunodeficiency Virus Infections | Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
-
EMD SeronoCompletedHuman Immunodeficiency Virus Infections | Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency Virus | Infections, Human Immunodeficiency Virus and HerpesviridaeUnited States
-
bioLytical LaboratoriesNot yet recruitingHuman Immunodeficiency Virus I Infection | Human Immunodeficiency Virus II Infection
-
Janssen R&D IrelandCompletedHuman Immunodeficiency Virus Type 1United States, France, United Kingdom, Belgium, Spain, Switzerland, Sweden, Canada, Puerto Rico, Poland
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency VirusUnited States
-
ViiV HealthcareGlaxoSmithKlineTerminatedInfection, Human Immunodeficiency VirusSpain, France, Germany
Clinical Trials on 3BNC117-LS
-
International AIDS Vaccine InitiativeBrigham and Women's Hospital; Fred Hutchinson Cancer Center; Rockefeller UniversityActive, not recruitingHIV-1-infectionUnited States, Uganda, Kenya, Rwanda, South Africa
-
AIDS Clinical Trials GroupNational Institute of Allergy and Infectious Diseases (NIAID)Not yet recruiting
-
AIDS Clinical Trials GroupNational Institute of Allergy and Infectious Diseases (NIAID)Not yet recruitingHIV-1-infectionMalawi, South Africa, Botswana
-
National Institute of Allergy and Infectious Diseases...Rockefeller UniversityWithdrawnHIV InfectionsUnited States
-
National Institute of Allergy and Infectious Diseases...Recruiting
-
Rockefeller UniversityCompleted
-
Imperial College LondonBill and Melinda Gates Foundation; University of Oxford; Rockefeller UniversityRecruitingHIV/AIDS and InfectionsDenmark, United Kingdom
-
Gilead SciencesCompleted
-
Rockefeller UniversityCompletedHuman Immunodeficiency VirusUnited States
-
Rockefeller UniversityNational Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaboratorsCompletedHuman Immunodeficiency VirusUnited States